Menopause Treatment Market Growth, Trends and Value Chain 2020-2027

 Market Research Future (MRFR) suggests in its new exhaustive study that the Menopause Treatment Market can expect to touch USD 15,456.3 Million by 2027. It is quite possible for the market size to expand at a lucrative rate of 6.18% over the assessment period (between 2020 and 2027).

COVID-19 Analysis

The COVID-19 outbreak has left a debilitating impact on the menopause treatment market, with the temporary shutdown of manufacturing facilities and weakened demand. Even as the world is trying to curb the spread of SARS-CoV-2, top companies are striving to bolster their supply chains and accelerate their operations to control further losses. They are also putting in efforts with respect to research and development and enter joint ventures to address the financial issues arising from the pandemic. Additionally, with the gradual lifting up of the lockdown across countries and the novel coronavirus under control, the global market can recover faster in the coming years.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4579 

Segment Analysis

The global menopause treatment market is segmented based on treatment and distribution channel.

The global menopause treatment market based on the treatment has been segmented into hormonal treatment and non-hormonal treatment. The hormonal treatment segment is further segmented into estrogen, progesterone, and combination. The non-hormonal treatment is further segmented into anti-depressants and others.

Based on distribution channel, the menopause treatment market is segmented into hospital pharmacies, retail pharmacies, and online stores.

Regional Analysis

The global menopause treatment market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and Middle East & Africa.

The Americas has been segmented into North America and Latin America, with the North America market further divided into the US and Canada. The Americas led the market and accounted for the largest share in 2019 owing to the increasing product approvals and high uptake of new technology.  For instance, in July 2017, AMAG Pharmaceuticals, Inc. (US) launched Intrarosa (prasterone) for the treatment of moderate to severe dyspareunia a symptom of vulvar and vaginal atrophy (VVA), due to menopause. Thus, such strategies employed by major players aid in the increased growth rate for the Americas menopause treatment industry.

The European menopause treatment market has been further segmented into Western Europe and Eastern Europe. The Western Europe menopause treatment market has further been classified into Germany, France, the UK, Italy, Spain, and the rest of Western Europe. Europe follows the Americas in the global menopause treatment market. The increasing inclination of companies towards female technology (femtech) is boosting the growth of the menopause treatment market in European countries. Many digital health start-ups have identified this opportunity and are offering B2C digital health tools, such as mobile apps, to guide menopausal women through this phase with lifestyle intervention tips and online telehealth consultations. As a result, the region is expected to show significant growth in the menopause treatment market.

The menopause treatment market in Asia-Pacific has been segmented into China, India, Japan, South Korea, Australia, and the rest of Asia-Pacific. Asia-Pacific is expected to register the highest growth rate over the forecast period from 2020 to 2027. This is owing to the growing penetration of the women’s health sector, increasing awareness about the betterment of the women’s health, and the growing number of educational campaigns related to the benefits of hormone replacement therapy in China, Japan, India, and Australia.

The Middle East & Africa menopause treatment market is segmented Saudi Arabia, the United Arab Emirates (UAE), Oman, Kuwait, Qatar, and the rest of the Middle East & Africa. The negative connotation of menopause has resulted in a negative attitude towards menopause in premenopausal women. However, with the increasing awareness created by private companies, the scenario is expected to change in the next ten years.

Key Players

MRFR recognizes the following companies as the Key Players in the Global Menopause Treatment Market— Novo Nordisk A/S (Denmark), Pfizer Inc. (US), Allergan (Ireland), Eli Lily and Company (US), Emcure Pharmaceuticals Ltd (India), Novartis AG (Switzerland), Cipla Inc. (India), Teva Pharmaceuticals (Israel), Merck & Co., Inc. (US), Abbott Laboratories (US).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/menopause-treatment-market-4579 

Nebulizers Market to Witness Widespread Expansion During 2020-2027

 Global Nebulizers Market is expected to hold a value of USD 1,629.7 Million by 2027 and is expected to register a growth of 7.32% from 2020 to 2027.

Nebulizers Market Synopsis

Nebulizers are a device that has the capability of changing a medication from a liquid to a mist so that it can be inhaled into the lungs. High demand for respiratory devices, including nebulizers, due to the outbreak of COVID-19 globally, growing need for rescue medication, increasing prevalence of respiratory diseases, and rising demand for home healthcare devices are the key factors that are expected to drive the market growth. Moreover, the growing geriatric population, increasing consumption of alcohol, tobacco, cigarettes, and other such products may lead to respiratory diseases, and the rising number of initiatives taken by the government as well as the private organizations are also expected to boost the market growth.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/9586 

The growth of the global nebulizers market can be contributed to the growing need for rescue medication, high demand for respiratory devices, including nebulizers, due to outbreak of COVID-19 globally, and increasing prevalence of chronic respiratory diseases. According to a press release from Icon Plc in April 2020, the demand for respiratory devices has enormously increased, due to the rising cases of COVID-19.

Furthermore, the growing demand for home healthcare devices, rising geriatric population, increasing consumption of alcohol, tobacco, cigarettes, and other such products that might lead to respiratory diseases, are also expected to fuel the market growth during the forecast period.

However, the loss of drug during nebulization procedures, availability of various substitutes for nebulizers, and side effects of nebulizer solutions are expected to restrain the growth of the global nebulizers market.

Several market players such as OMRON Healthcare, Koninklijke Philips N.V., and B. Braun Melsungen AG, among others currently dominate the global nebulizers market. The key players are involved in awareness campaigns, product approvals, mergers, and strategic collaborations to strengthen their market positions. For instance, in April 2020, B. Braun Melsungen AG received the Food and Drugs Administration (FDA) emergency use authorization for using its infusion pumps with nebulizers to treat COVID-19 patients.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas region held the largest market in 2019, owing to the rising demand for respiratory diseases in the region. The nebulizers market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European nebulizers market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The nebulizers market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing incidence rate of respiratory diseases, the market in Asia-Pacific is expected to be the fastest-growing. The nebulizers market in the Middle East & Africa has been divided into the Middle East and Africa.

Segmentation

The Global Nebulizers Market has been Segmented Based on the Type, Usage, Portability, and End User.

Based on the Type, the global nebulizers market has been segmented into mesh, jet, and ultrasonic. The mesh segment is further divided into active and passive. The jet segment is expected to hold the largest market share owing to its low cost as compared to other types of nebulizers.

On the basis of usage, the market has been segmented into reusable and disposable. The disposable nebulizers are expected to hold a major market share owing to their growing popularity amongst the users.

Based on the portability, the market has been segmented into tabletop and portable. The portable nebulizers market is expected to grow at the fastest CAGR owing to its ease and convenience of use.

The market based on end-user has been segmented into hospitals & clinics, home care, and others. The hospitals and clinics segment is expected to hold the largest market share owing to the larger patient footfall in hospitals.

Key Players

Some of the key players in the global nebulizers market are OMRON Healthcare (Japan), Koninklijke Philips N.V. (Netherlands), PARI (US), Vectura Group plc (UK), Rossmax International Ltd (Taiwan), Briggs Healthcare (US), GF Health Products, Inc. (US), Beurer GmBH (Germany), Agilent Technologies, Inc. (US), Drive DeVilbiss Healthcare (US), Invacare Corporation (US), and B. Braun Melsungen AG (Germany).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/nebulizers-market-9586 

Global Electronic Trial Master File (eTMF) Systems Market Show Steady Growth: Study 2027

 Global eTMF Systems Market is expected to reach a value of USD 1825 Million by 2025, at a CAGR of 13.11% during the assessment period of 2019 to 2025.

Electronic Trial Master File Systems Market Synopsis

The pharmaceutical, as well as the biotechnology companies, face a major challenge to maintain a central repository for the storage of clinical trial documents for use in regulatory submissions. Therefore, there emerges a need to store all the data produced by these companies effectively. As a result, software companies have developed electronic trial master file systems that aid these companies as well as the contract research organizations in systemized storage of files. Moreover, in comparison to the traditional storage systems, electronic trial master file systems facilitate content classification and easier interoperability in clinical trial operations. Therefore, the major companies are continuously involved in new product launches to gain a competitive edge over the other players.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8772 

The growth of the global eTMF systems market is fueled by several factors such as rising activities in terms of acquisitions, new solution and service deployments, and collaborations by key players operating in the market, coupled with the increasing number of clinical trial studies. For instance, in October 2019, SureClinical Inc. launched a transparent eTMF pricing policy. To provide value to the prospective users, the company has posted its prices and terms online to battle price discrimination in this industry. However, budget constraints of the small and medium-sized enterprises, along with the dearth of skilled professionals for operating the electronic systems, can hinder the preference of such solutions. As a result, such elements can hamper the growth of the market during the forecast period.

Several market players currently dominate the global eTMF systems market. The key players are involved in product launches and strategic collaborations to strengthen their market positions. For instance, in June 2018, Phlexglobal, a UK-based specialist provider of TMF and eTMF management solutions, is adopting Version 1 of the eTMF Exchange Mechanism Standard (eTMF-EMS) of the TMF Reference Model (TMF-RM) into PhlexEview, the company’s eTMF technology. Such strategies push the growth of the eTMF systems market.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas held the maximum share in the base year 2018, owing to the presence of established key players in countries such as the US and Canada. The eTMF systems market in the Americas has been segmented into North America and Latin America, with the North American market divided into the US and Canada. The European eTMF systems market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The eTMF systems market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The eTMF systems market in this region is anticipated to be the fastest-growing during the assessment period due to the increased adoption rate of eTMF software and services in the Asian countries. The eTMF systems market in the Middle East & Africa has been divided into the Middle East and Africa.

Segmentation

The Global eTMF Systems Market has been segmented based on Component, Deployment Mode, and End User.

The global eTMF systems market has been segmented, based on the component, into software and services. The software segment is expected to hold the majority share of the market owing to the increasing number of solution launches by the prominent players in recent years. The services segment is expected to be the fastest-growing due to the increasing uptake of eTMF services by pharmaceutical and life science companies.

The global eTMF systems market, based on deployment model, has been segmented into cloud/web-based, and on-premise. The cloud/web-based segment holds the maximum share owing to the technological advancements in cloud-based solutions in recent years.

The end-users of the market are pharmaceutical and biotechnology companies, contract research organizations, and others. The increasing number of clinical trials conducted by pharma firms is leading to the market size of the pharmaceutical and biotechnology companies’ segment.

Key Players

Some of the Key Players in the Global eTMF Systems Market are Aurea, Inc. (US), Covance Inc. (US), ePharmaSolutions (US), MasterControl, Inc. (US), Oracle (US), Phlexglobal (UK), SureClinical Inc. (US), TransPerfect (US), Veeva Systems (US), and Wingspan (IQVIA) (US).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/etmf-systems-market-8772 

Safety Lancet Market to Witness Widespread Expansion During 2020-2027

 According to the latest report, the global safety lancet market is predicted to reach USD 2,305.1 Million by the end of the year 2023 from USD 1,056.2 Million in the year 2016 with registering a CAGR of 11.8% during the forecast period of 2017 to 2023. A safety lancet is a small piece of medical equipment that is used for capillary blood sampling; it looks like a scalpel attached to a double-edged needle or blade. Lancets are a single user device and can be used for punchers, as for example finger sticks in order to obtain small blood specimens. A safety blood lancet is basically disposable.

The safety lancet market is a vital and dynamic component of the healthcare industry. The rise in developments in the devices of the healthcare industry such as treatment and prevention of several diseases and diagnosis is the major factor contributing to the growth of the global safety lancet market. All the components of the health care industry play an important role in the global safety lancet market size.  The increasing chronic diseases such as dyslipidemia, diabetes, and hyperlipidemia, and the increasing incidents of homecare diagnosis are some other major factors contributing to the growth of the global safety lancet market.  Moreover, the high demand for the use of disposable blood lancet for pain-free diagnosis of hemoglobin, fat level, blood sugar level, and other important blood components are lily to propel the growth of the global safety lancet market. The disposable lancet decreases the risk of the transmission of infection and blood transfusion which is again contributing to the growth of the global blood lancet market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/550 

Various factors are propelling the safety lancet market growth. These factors, as stated by the MRFR report, include growing geriatric population, rise in awareness regarding advanced technology, increase in the prevalence of chronic diseases such as dyslipidemia, hyperlipidemia, and diabetes, and increase in reimbursement policies. Additional factors boosting market growth include increasing inclination towards healthcare, improving medical device regulation, growing government support, increasing research and development activities in surgical equipment, and rising healthcare spending.

On the contrary, lack of patient awareness and high cost of the product are factors that may impede the safety lancet market growth over the forecast period.

Market Segmentation

The Market Research Future report provides a wide segmental analysis of the safety lancet market based on the type and end user.

By type, the safety lancet market is segmented into side button safety lancet, pressure activated

safety lancet, and push-button safety lancet. Of these, the push-button safety lancet segment will dominate the market over the forecast period.

By end user, the safety lancet market is segmented into home diagnostics, diagnostic centers and pathology laboratories, hospitals and clinics, and others. Among these, the hospitals and clinics segment will lead the market over the forecast period.

Regional Analysis

Based on the region, the safety lancet market report covers the latest trends and growth opportunities across the Asia Pacific (APAC), Europe, North America, and the Middle East and Africa (MEA). Of these, Europe will spearhead the market over the forecast period. This is owing to the growing need and demand for safe blood glucose tests in hospitals and clinics and diagnostic centers coupled with an increase in insulin users. It is predicted to touch USD 1,032.7 million. Germany, France, and the UK are the key contributors in this region.

The safety lancet market in North America is predicted to have a faster growth over the forecast period owing to the testing of newborn babies for diseases being mandatory under the budget-friendly healthcare act. The US is the key contributor in this region.

The safety lancet market in the Middle East and Africa is predicted to have a steady growth over the forecast period owing to low healthcare expenditure and poor economic conditions in Africa.

Key Players

Leading players profiled in the safety lancet market report include Sarstedt AG & Co., Dickinson and Company, F. Hoffmann-La Roche AG, Improve Medical Technology Co. Ltd, Becton, HTL-STREFA S.A., Bayer AG, and Terumo Medical Corporation, among others. Key players have acquired some strategies such as acquisition, mergers, product development, and innovation to create a niche in the market.

December 2018- In response to the burgeoning demand for a convenient and safe means to dispose of used or unwanted lancets and medical needles, Sanford Health has installed sharps disposable drop-box kiosk.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/safety-lancet-market-550 

Global Transarterial Chemoembolization (TACE) Market size and forecast, 2020-2027

 Transarterial Chemoembolization (TACE) Market is expected to cross USD 2777.22 Million by 2025 at a CAGR of 8.57%.

The increasing prevalence of liver cancer is expected to drive the growth of the global transarterial chemoembolization (TACE) market. Hepatocellular carcinoma (HCC) is fifth cancer in terms of incidence and the second leading cause of cancer death for men worldwide. The incidence of HCC is highest in Asia and Africa.

Market Synopsis

Transarterial chemoembolization is the current standard of therapy for patients with intermediate-stage hepatocellular carcinoma (HCC). Conventional TACE is considered as a standard treatment for HCC. However, systemic toxicity induced by conventional TACE in some cases has led to the introduction of drug-eluting bead TACE. DEB-TACE uses microspheres as drug carriers, which reduces the concentration of chemotherapeutic in the systemic circulation of patients.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8564 

Segmentation

By Procedure Type

• Conventional TACE: Conventional TACE dominated the Transarterial chemoembolization (TACE) market as it is one of the oldest procedures used in HCC cases. Conventional TACE involves the infusion of chemotherapeutic drugs blended with lipiodol and embolic agents into the cancer-feeding artery

• DEB-TACE: This segment is expected to witness the fastest growth. DEB-TACE allows higher concentrations of drugs to the target tumor and lower systemic concentrations, compared with conventional TACE

By Indication

• Unresectable HCC: TACE is a major treatment modality for unresectable HCC. The liver tumor which is not eligible for resection therapy given the extent of disease is considered as unresectable HCC

• Early-Stage HCC: In case of early-stage HCC, TACE is recommended if resection or local ablation is not feasible

By Product Type

• Chemotherapeutic Agents: Held the largest market share in 2018. Doxorubicin, cisplatin, and mitomycin are most commonly used in the TACE procedure. Doxorubicin is the most widely used chemotherapeutic agent for TACE of HCC. The dose of doxorubicin generally ranges from 30 to 75 mg/m2

• Radiotherapeutic Agents: TACE with radiotherapeutic agents is the most expensive treatment for liver tumors.

• Drug-eluting Particles: Drug-eluting beads have been imposed as novel drug-delivering agents for TACE. DC Beads is one of the most commonly used Drug-eluting beads. These beads are nonbiodegradable PVA microspheres, loaded with calibrated doxorubicin

By End-User

• Hospitals & Clinics: It holds the largest market share that can be attributed to an increase in the number of patients afflicted by HCC, coupled with a rise in a number of hospitals, and quality care, and availability of skilled and qualified professionals.

• Cancer Research Centers: This is the fastest-growing segment due to increasing research funding for the development of effective treatment of HCC

By Region

• Americas: The region holds the largest share of the market. The market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada.

• Europe: The European transarterial chemoembolization (TACE) market has been classified as Western Europe and Eastern Europe. The Western European market has further been categorized as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

• Asia-Pacific: The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Asia-Pacific transarterial chemoembolization (TACE) market is projected to be the fastest-growing during the forecast period.

• Middle East & Africa: The market in the Middle East & Africa has been divided into the Middle East and Africa.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/transarterial-chemoembolization-market-8564 

Tissue Microarray Market to Witness Widespread Expansion During 2020-2027

 According to the latest report, the global tissue microarray market size is predicted to reach USD 10,914.54 Million by the end of the year 2023 with a growth rate of 10.54% CAGR, during the forecast period. Tissue microarray is paraffin blocks where up to 1000 separate cylindrical tissue cores can be assembled in an array fashion which allows analyzing of molecules that are present n DNA, mRNA, and protein levels under similar standardized conditions on a single glass slide. This versatile strategy where data automated analysis provides prospective and retrospective human tissue studies.

The rising applications in discovery of drugs, the increasing advancements in pharmaceutical companies and biotechnology, rising generality of cancer, and increasing demand for accurate and cost-effective diagnostic methods are the major factor that is contributing to the growth of the global tissue microarray market. Array-based technology offers platforms for profiling of tissues such as DNA array and tissue array and disease genes; thousand of genres have been identified with the help of tissue microarray technology which can be associated with progression, initiation, and development. Moreover, tissue microarray is not beneficial for heterogeneous cancers and it is likely to create hurdles in the growth of the global tissue microarray market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1213 

Increasing application of tissue microarray in drug discovery and oncology, automated analysis of results, and influence of technology are some of the major factors that fosters the growth of the global tissue microarray market. Moreover, wide applications of tissue microarray in pathology is another factor, which is impelling the growth of tissue microarray market. 

Major Players in the tissue microarray Market

Some of the key players in the global market are Agilent Technologies, Illumina, Inc., Protein Biotechnologies Inc., Asterand Bioscience, Pantomics Inc., Applied Microarrays, Arrayit, Phalanx Biotech, Qiagen, Takara Bio, Perkin Elmer, Merck Sharp & Dohme Corp, and general electric and others.

The global tissue microarray market consists of four regions: the Americas, Europe, Asia Pacific, and the Middle East & Africa.

The Americas is the leading market across the globe on account of constantly increasing cancer patient population, increasing number of cases in children, and increasing government support for research in healthcare domain and it is likely to flourish the Americas market over the review period.

Europe holds the second position in the market due to development in healthcare domain. During the last 30 years, in Europe biotechnology industry has developed gradually. Even though in Germany federal support programs started very early to target biotechnology, the innovative performance of this sector has been lagging behind that of the US, where the federal support was less direct earlier. Advances in technology in the healthcare sector have minimized human effort and increased the quality of patient care services, which will boost the market growth.

Asia Pacific is expected to be the fastest growing market owing to the concentration of emerging player and focus of established market leaders in this region. Moreover, the rising incidence of cancer in Asia Pacific has prompted suppliers and manufacturers to expand their market reach and to enter emerging markets. According to the Centers for Disease Control and Prevention (CDC), life-threatening or chronic diseases such as stroke, heart disease, cancer, diabetes, and chronic respiratory diseases, kidney diseases were the leading cause of death in 2014.  

On the other hand, the Middle East & Africa owns the minimum market share of the tissue microarray market due to less development in healthcare services such as new and advanced diagnosis & treatment methods in healthcare domain.

Segmentation

The global tissue microarray market is segmented on the basis of procedure, technology, application, and end user.

On the basis procedure, it is segmented into immunohistochemistry, fluorescent in-situ hybridization, and frozen tissue array.

On the basis of technology, it is segmented into DNA microarray, polymerase chain reaction, next-generation sequencing,     northern blotting, and western blotting.

On the basis of application, it is segmented in to oncology, gene expression profiling, SNP detection, double-stranded B-DNA microarrays, and comparative genomic hybridization, and sequencing bioinformatics.

On the basis of end user, it is segmented into pharmaceutical and biotechnological companies, research organization, and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/tissue-microarray-market-1213 

Thumb Arthritis Market to Witness Widespread Expansion During 2020-2027

 Thumb or carpometacarpal (CMC) joint arthritis is a common type of arthritis affecting the hands. In the patients with thumb arthritis, the cushion-like cartilage inside the CMC joint breaks down, causing the bones to rub against each other. Some of the common symptoms of the disease are inclusive of thumb joint pain, thumb base swelling, besides others. The prevalence of the thumb arthritis is increasing which is the major driver for the market growth. In 2016, according to a study published in the HAND (American Association for Hand Surgery) journal, the prevalence of the thumb CMC osteoarthritis was estimated to be around 8% to 12% in the general population. Moreover, growing geriatric and obese population along with the rising healthcare expenditure is estimated to boost the market growth during the forecast period. According to the World Health Organization in 2016, approximately more than 1.9 billion adults, were estimated to be overweight, accounting for 650 million obese people. Additionally, according to the World Health Organization, the world’s geriatric population is estimated to reach 2 billion by 2050 from 900 million in 2015. However, the high cost of the surgical therapeutics along with related complications is estimated to restrain the market growth during the forecast period. According to a study published in the Plastic and Reconstructive Surgery journal in 2016, the cost of therapeutic trapeziectomy with LRTI for a majority of the patients (89%) was estimated to be about around USD 2,576.

The Global Thumb Arthritis Market is expected to grow at an approximate CAGR of 8.1% during the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5238 

Segmentation

The global thumb arthritis market is segmented on the basis of type, diagnosis, treatment, and end user. On the basis of the type, the market is segmented into osteoarthritis thumb arthritis, rheumatoid thumb arthritis, and others. On the basis of the diagnosis, the market is segmented into physical examinations, imaging, fine needle aspiration (FNA), and others. The imaging segment is sub-segmented into X-ray, computed tomography (CT), magnetic resonance imaging (MRI), and others.

On the basis of the treatment, the market is segmented into thumb exercise, medication, surgery, and others. The medication segment is sub-segmented into OCT medications, prescription medications, and others. The surgery segment is sub-segmented into trapeziectomy, osteotomy, and others.

On the basis of the end users, the market is segmented into hospitals & clinics, research organizations, retail pharmacies, and others.

Regional Analysis

The Americas dominate the global thumb arthritis market. A well-developed healthcare sector, growing geriatric population, and increasing healthcare expenditure are the major drivers for the growth of the global thumb arthritis market.

Europe holds the second largest thumb arthritis market owing to the availability of the funds for research, increasing surgery adoption rates, and growing patient population. According to the Office for National Statistics the geriatric population within the region is expected to grow and reach 20.5% of the total U.K population by 2026 from 18.0% in 2016.

Asia Pacific is the fastest growing region. Growing geriatric and obese population followed by the developing healthcare sector are boosting the market growth. Within the region, Australia holds a significant ratio of the obese population. However, the presence of the developing economies like India and China are marked by expanding healthcare sector. This is estimated to provide favorable backgrounds for the market growth.

The Middle East and Africa region account for the least market share. This is mainly due to the presence of the poor African economies within the region, which have low per capita income and lack of the medical services. On the other, the Middle East holds the largest market share within the region.

Key Players

The key players in the global thumb arthritis market are inclusive of BioPro (U.S.), McKie Splints (U.S.), AbbVie Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Amgen Inc. (U.S.), Pfizer Inc. (U.S.), Carestream Health. (U.S.), General Electric Company (U.K), and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/thumb-arthritis-market-5238